Patents Assigned to Mitsubishi Pharma Corporation
-
Publication number: 20070166825Abstract: The present invention provides useful means in an expansion culture system for a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell). Specifically, the present invention provides a composition for expanding a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell) containing recombinant human serum albumin; a serum-free medium for expanding a hematopoietic cell containing a basal medium and recombinant human serum albumin; a method of expanding a hematopoietic cell comprising culturing a hematopoietic cell in a serum-free medium containing recombinant human serum albumin, and a culture of a hematopoietic cell that can be obtained by the expansion method.Type: ApplicationFiled: July 21, 2004Publication date: July 19, 2007Applicant: Mitsubishi Pharma CorporationInventors: Asako Hatsuyama, Kiminari Ito, Tatsutoshi Nakahata
-
Publication number: 20070167455Abstract: The invention relates to therapeutic uses of a 2-(diaza-bicyclo-alkyl)-pyrimidone derivative represented by formula (I): Wherein R1, R2, R3, R4 and n are as defined herein. Specifically, the compounds of formula (I) are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer's disease. The invention relates also to intermediates for the preparation of compound of formula (I).Type: ApplicationFiled: March 29, 2007Publication date: July 19, 2007Applicants: SANOFI-AVENTIS, MITSUBISHI PHARMA CORPORATIONInventors: Alistair LOCHEAD, Mourad SAADY, Franck SLOWINSKI, Philippe YAICHE
-
Publication number: 20070161620Abstract: The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.Type: ApplicationFiled: March 19, 2007Publication date: July 12, 2007Applicant: Mitsubishi Pharma CorporationInventors: Masakazu Fujio, Hiroyuki Satoh, Shinya Inoue, Toshifumi Matsumoto, Yasuhiro Egi
-
Patent number: 7232827Abstract: The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: (I) X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring optionally substituted; R2 represents a heterocyclic bicyclic rings, having 1–4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom and having 5–9 carbon atoms, of formula (II) R3 represents a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6 alkyl group, a C1-4 alkoxy group or a halogen atom.Type: GrantFiled: February 26, 2003Date of Patent: June 19, 2007Assignees: Sanofi-Aventis, Mitsubishi Pharma CorporationInventors: Alistair Lochead, Alain Nedelec, Mourad Saady, Philippe Yaiche
-
Patent number: 7220759Abstract: The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.Type: GrantFiled: April 30, 2004Date of Patent: May 22, 2007Assignee: Mitsubishi Pharma CorporationInventors: Masakazu Fujio, Hiroyuki Satoh, Shinya Inoue, Toshifumi Matsumoto, Yasuhiro Egi
-
Patent number: 7217539Abstract: A cell death inducer for mast cells, a preventive/therapeutic agent for diseases in which mast cells are implicated, having a fusion protein including a PTD and an MITF variant as an active ingredient and a fusion protein comprises a His Tag, a PTD, and an MITF variant, wherein the MITF variant being an MITF mi variant, wh variant, HLH fragment, or A-type N-terminal region (1-305) fragment, and the PTD being a TAT-derived peptide; DNA coding for the fusion protein; and a method for preparing the fusion protein using genetic engineering techniques. Actions of the fusion protein of the present invention include inhibiting an activity of endogenous MITF by translocating into mast cells, inhibiting a survival of mast cells derived from precursor cells, and inducing cell death (apoptosis) in mature mast cells.Type: GrantFiled: July 4, 2002Date of Patent: May 15, 2007Assignee: Mitsubishi Pharma CorporationInventors: Koji Naito, Shusei Uno, Eiji Asakura
-
Patent number: 7217715Abstract: The invention relates to a substituted-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.Type: GrantFiled: September 13, 2005Date of Patent: May 15, 2007Assignees: Sanofi-Aventis, Mitsubishi Pharma CorporationInventors: Alistair Lochead, Mourad Saady, Franck Slowinski, Philippe Yaiche
-
Patent number: 7214682Abstract: The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 may represent a C1-6 alkyl group optionally; a C3-6 cycloalkyl group, a C1-4 alkythio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represent, eacType: GrantFiled: September 19, 2002Date of Patent: May 8, 2007Assignees: Sanofi-aventis, Mitsubishi Pharma CorporationInventors: Thierry Gallet, Patrick Lardenois, Alistair Lochead, Séverine Marguerie, Alain Nedelec, Mourad Saady, Franck Slowinski, Philippe Yaiche
-
Patent number: 7211596Abstract: An injection which contains as the active ingredient a pyrazolone derivative which typically is Edaravone, a physiologically acceptable salt thereof, or a hydrate or solvate of either in an amount of 3 to 60 mg/mL. It is excellent in long-term stability, product storage, and suitability for use.Type: GrantFiled: May 9, 2002Date of Patent: May 1, 2007Assignee: Mitsubishi Pharma CorporationInventors: Hiroshi Yoshida, Naoki Matsuo, Masatoshi Chiba
-
Patent number: 7211581Abstract: The invention relates to a 2-(diaza-bicyclo-alkyl)-pyrimidone derivative represented by formula (I): wherein: R1 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group, a C1-4 alkoxy group; a C1-2 perhalogenated alkyl group, a benzyl group, a phenethyl group, a benzyloxycarbonyl group, a C1-4 alkoxy carbonyl group, a benzene ring, a naphthalene ring, a quinoline ring, a phthalazine ring, a 5,6,7,8-tetrahydronaphthalene ring, a pyridine ring, an indole ring, a pyrrole ring, a thiophene ring, a benzenesulfonyl group, a benzoyl group, a pyridazine ring, a furan ring and an imidazole ring; each of the benzyl group, the phenethyl group, the benzyloxycarbonyl group, the benzenesulfonyl group, the benzoyl group and the benzene, naphthalene, quinoline, phthalazine, 5,6,7,8-tetrehydronaphthalene, pyridine, indole, pyrrole and thiophene rings being optionally subType: GrantFiled: September 6, 2005Date of Patent: May 1, 2007Assignees: Sanofi-Aventis, Mitsubishi Pharma CorporationInventors: Alistair Lochead, Mourad Saady, Franck Slowinski, Philippe Yaiche
-
Patent number: 7208514Abstract: A compound having a xanthine oxidase inhibitory activity, such as 1-(3-cyano-4-neopentyloxyphenyl)pyrazole-4-carboxylic acid and the like, can be a drug for preventing cancer including colon cancer and the like, as an agent for suppressing tumorigenesis.Type: GrantFiled: March 12, 2004Date of Patent: April 24, 2007Assignee: Mitsubishi Pharma CorporationInventor: Norihisa Kato
-
Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby
Patent number: 7198921Abstract: The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene encoding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.Type: GrantFiled: May 16, 2001Date of Patent: April 3, 2007Assignee: Mitsubishi Pharma CorporationInventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi -
Patent number: 7199160Abstract: Antiobestic agents and health foods containing as the active ingredient substances having an effect of adsorbing bile acid in the digestive tract, an effect of inhibiting intestinal circulation or an effect of inhibiting the absorption of exogenous lipids typified by pharmaceutically acceptable anion exchange resins. In particular, antiobestic agents and health foods characterized by lowering body weight and/or visceral fat content without reducing food intake.Type: GrantFiled: October 9, 2001Date of Patent: April 3, 2007Assignee: Mitsubishi Pharma CorporationInventors: Kazuo Suzuki, Shigekazu Nakajima, Shinji Yano
-
Publication number: 20070074295Abstract: There are provided isolated polynucleotide fragments for use in diagnosing and/or developing treatments for schizophrenia. Further provided is a method for diagnosing schizophrenia using one or more polynucleotides disclosed herein. Also provided is a method for screening a compound which regulates expression of a schizophrenia-related gene. Also provided is a chronic animal model of schizophrenia that mimics the functional deficits observed in patients and methods for producing the animal model comprising the administration of PCP to the animal.Type: ApplicationFiled: September 11, 2006Publication date: March 29, 2007Applicant: Mitsubishi Pharma CorporationInventors: Susan Cochran, Gary Paterson, Yoshitaka Ohashi, Brian Morris, Judith Pratt
-
Patent number: 7196199Abstract: The present invention relates to a phenoxypropylamine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.Type: GrantFiled: December 22, 2003Date of Patent: March 27, 2007Assignee: Mitsubishi Pharma CorporationInventors: Akira Nishiyama, Masahiro Bougauchi, Takanobu Kuroita, Masanori Minoguchi
-
Patent number: 7166630Abstract: A method for promoting myelination of an axon comprising administering 4-[?-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is disclosed.Type: GrantFiled: October 22, 2004Date of Patent: January 23, 2007Assignee: Mitsubishi Pharma CorporationInventors: Masakazu Kawasaki, Nobuharu Gotoh, Yoshiharu Hayashi, Kazuyuki Kawasaki
-
Patent number: 7166617Abstract: Novel compounds represented by the following formula (I) that act as a ligand to sigma receptor/binding cite and a medicament comprising the same as an active ingredient: wherein X represents an alkyl group, an aryl group, a heterocyclic group or the like; Q represents a group represented by —CH2—, —CO—, —O—, —CH(OR7)— or the like wherein R7 represents a hydrogen atom, an alkyl group or the like; n represents an integer of from 0 to 5; R1 and R2 each represent a hydrogen atom, an alkyl group or the like; B represents either of the following groups: wherein R3, R4, R5, and R6 each represent a hydrogen atom, a halogen atom, an alkoxyl group or the like; m represents 1 or 2; and the ring of: represents an aromatic heterocyclic ring.Type: GrantFiled: February 26, 2001Date of Patent: January 23, 2007Assignee: Mitsubishi Pharma CorporationInventors: Haruko Yamabe, Masahiro Okuyama, Akira Nakao, Mitsuru Ooizumi, Ken-ichi Saito
-
Publication number: 20070010539Abstract: The invention relates to a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, o, m, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.Type: ApplicationFiled: June 12, 2006Publication date: January 11, 2007Applicants: SANOFI-AVENTIS, MITSUBISHI PHARMA CORPORATIONInventors: Nathalie CHEREZE, Alistair LOCHEAD, Mourad SAADY, Franck SLOWINSKI, Philippe YAICHE
-
Publication number: 20060287284Abstract: The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents preferably selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.Type: ApplicationFiled: October 21, 2003Publication date: December 21, 2006Applicants: Negma Gild, Mitsubishi Pharma CorporationInventors: Francois Schutze, Suzy Charbit, Hervé Ficheux, Michel Homerin, Alain Taccoen, Nathalie Taccoen, Yoshio Inaba
-
Patent number: 7115635Abstract: The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration. The present inventors have found that the following benzylpiperidine derivative (the formula (1)) has a chemokine inhibitory activity. Further intensive studies have resulted in successful enhancement of the chemokine inhibitory activity and stability in blood of the present compound, as well as the completion of the present invention. wherein each symbol is as defined in the specification.Type: GrantFiled: April 26, 2002Date of Patent: October 3, 2006Assignee: Mitsubishi Pharma CorporationInventors: Masatoshi Kiuchi, Takanobu Kuroita, Hideo Tomozane, Shuuzou Takeda, Yoshihito Tanaka, Hidemitsu Higashi, Shigeki Kuwahara